Cargando…

Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences

Plasma ACE2 activity is persistently elevated in patients after COVID-19 infection. Larger studies are needed to determine if this identifies people at risk of prolonged illness following COVID-19. https://bit.ly/2XQlrYF

Detalles Bibliográficos
Autores principales:	Patel, Sheila K., Juno, Jennifer A., Lee, Wen Shi, Wragg, Kathleen M., Hogarth, P. Mark, Kent, Stephen J., Burrell, Louise M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Agora
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830336/ https://www.ncbi.nlm.nih.gov/pubmed/33479113 http://dx.doi.org/10.1183/13993003.03730-2020

Ejemplares similares

Elevated ACE-2 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and replication
por: Chen, Mengfei, et al.
Publicado: (2020)

Smoking, ACE-2 and COVID-19: ongoing controversies
por: Leung, Janice M., et al.
Publicado: (2020)

COVID-19 and nicotine as a mediator of ACE-2
por: Leung, Janice M., et al.
Publicado: (2020)

ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19
por: Leung, Janice M., et al.
Publicado: (2020)

Could the smoking gun in the fight against COVID-19 be the (rh)ACE-2?
por: Lutchman, Dhamend
Publicado: (2020)

Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects
por: Jacobs, Merel, et al.
Publicado: (2020)

mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19
por: Tang, Yan, et al.
Publicado: (2021)

Reply to: Cause or consequence?
por: Bateman, Eric D., et al.
Publicado: (2022)

Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors
por: Motiejunaite, Justina, et al.
Publicado: (2021)

Reduction in asthma admissions during the COVID-19 pandemic: consequence of public health measures in Singapore
por: Wee, Liang En, et al.
Publicado: (2021)

Plasma mediators in patients with severe COVID-19 cause lung endothelial barrier failure
por: Michalick, Laura, et al.
Publicado: (2021)

COVID-19 in Italy: passing through bitter waters
por: Guglielmetti, Lorenzo, et al.
Publicado: (2020)

P(aO(2))/F(IO(2)) ratio: the mismeasure of oxygenation in COVID-19
por: Tobin, Martin J., et al.
Publicado: (2021)

Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma
por: Busse, William W., et al.
Publicado: (2021)

Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial
por: Milne, Stephen, et al.
Publicado: (2021)

Impact of the SARS-CoV-2 epidemic on tuberculosis treatment outcome in Northern Italy
por: Magro, Paola, et al.
Publicado: (2020)

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2
por: Yang, Hai-Jun, et al.
Publicado: (2020)

COVID-19 and vaping: risk for increased susceptibility to SARS-CoV-2 infection?
por: McAlinden, Kielan Darcy, et al.
Publicado: (2020)

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2
por: Du, Rong-Hui, et al.
Publicado: (2020)

Autoimmunity to annexin A2 predicts mortality among hospitalised COVID-19 patients
por: Zuniga, Marisol, et al.
Publicado: (2021)

Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab
por: Lindner, Andreas K., et al.
Publicado: (2021)

Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal swab
por: Lindner, Andreas K., et al.
Publicado: (2021)

Socioeconomic correlates of SARS-CoV-2 and influenza H1N1 outbreaks
por: Kaiser, Jan Christian, et al.
Publicado: (2020)

Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection
por: Frija-Masson, Justine, et al.
Publicado: (2020)

Saliva molecular testing for SARS-CoV-2: simplifying the diagnosis without losing accuracy
por: Saluzzo, Francesca, et al.
Publicado: (2021)

Asthma, COPD and SARS-CoV-2 infection (COVID-19): potential mechanistic insights
por: Wark, Peter A.B., et al.
Publicado: (2021)

Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients
por: Yu, Hai-qiong, et al.
Publicado: (2020)

Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection
por: Trinkmann, Frederik, et al.
Publicado: (2021)

SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network
por: van Koningsbruggen-Rietschel, Silke, et al.
Publicado: (2020)

Utility and safety of bronchoscopy during the SARS-CoV-2 outbreak in Italy: a retrospective, multicentre study
por: Mondoni, Michele, et al.
Publicado: (2020)

Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?
por: Criel, Maarten, et al.
Publicado: (2020)

SARS-CoV-2 infections in people with primary ciliary dyskinesia: neither frequent, nor particularly severe
por: Pedersen, Eva S.L., et al.
Publicado: (2021)

The association between SARS-CoV-2 RT-PCR cycle threshold and mortality in a community cohort
por: Waudby-West, Rupert, et al.
Publicado: (2021)

Exercise capacity impairment after COVID-19 pneumonia is mainly caused by deconditioning
por: Jahn, Kathleen, et al.
Publicado: (2022)

Characteristics and outcomes of health and social care workers testing positive for SARS-CoV-2 in the Tayside region of Scotland
por: Siddiqui, Moneeza K., et al.
Publicado: (2020)

Does chemotherapy reactivate SARS-CoV-2 in cancer patients recovered from prior COVID-19 infection?
por: Bi, Jianping, et al.
Publicado: (2020)

Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?
por: Ndjeka, Norbert, et al.
Publicado: (2020)

ORF8/ORF8a: a difference between SARS-CoV-2 and SARS-CoV
por: Zandi, Milad
Publicado: (2022)

Wnt5a and Wnt11 as acute respiratory distress syndrome biomarkers for severe acute respiratory syndrome coronavirus 2 patients
por: Choi, Eun Young, et al.
Publicado: (2020)

A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
por: Singh, Dave, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_civu1cijgmf9a1m438vs4tc3dj